Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 01 May, 2020

JP Morgan Sec LLC

Willis Towers Watson plc 8.3

RNS Number : 6867L
J.P. Morgan Securities LLC
01 May 2020
 

Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL 

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

J.P. Morgan Securities LLC

Companydealtin

Willis Towers Watson plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

US$0.000304635 ordinary shares

Date of dealing

30 April 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 747,684  0.58

1,204,507  0.94

(2) Derivatives (other than options)

 565,550  0.44

674,960  0.52

(3)Optionsandagreementstopurchase/sell

 

 

Total

 1,313,234  1.02

1,879,467  1.46

             

 

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit (Note 5)

USD

Purchase (New Borrow)

 

Purchase

 

 

 

 

 

 

 

 

 

 

 

 

 

Sale

8,600

 

100

151

1,342

61

900

61

900

15

1

90

66

15,884

16

 

151

8

7

61

61

900

200

200

100

400

90

1,500

100

66

100

600

100

4

28

2

100

100

1,100

12,515

300

18

400

40

300

100

116

100

100

100

NA

 

175.7300

176.0000

176.4203

177.2500

177.2667

177.2700

177.2717

177.5000

177.5250

177.8700

177.9400

178.2900

178.8300

 

176.0000

176.3500

177.0500

177.2500

177.2700

177.2717

177.3081

177.4045

177.5827

177.7702

177.8700

177.9113

177.9237

177.9400

177.9949

178.0039

178.1041

178.1053

178.1219

178.1500

178.2311

178.2777

178.2782

178.2900

178.3387

178.4056

178.5547

178.5744

178.6267

178.6512

178.6529

178.9052

178.9433

178.9583

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

  (USD)

(Note 5)

Equity Swap

Sale

900

76

177.2717

178.2900

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. 

If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Dateofdisclosure

1 May 2020

Contact name

Alwyn Basch

Telephone number

0207 742 7407

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

N/A

If aconnectedEFM,statenatureofconnection (Note 10)

N/A

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFFLFBBELFBBK

a d v e r t i s e m e n t